Mab 17-1A
Rectal Cancer Dukes B, Dukes C
Austrian Breast & Colorectal Cancer Study GroupPhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
70 Active assets in the Rectal Cancer Dukes B, Dukes C cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Sun Yat-sen University | Phase 4 | BBB |
FLUOROURACILUM Seoul National University Hospital | Phase 3 | BBB |
Eloxatin Sun Yat-sen University | Phase 3 | BBB |
Capecitabine Tao Zhang | Phase 3 | BB |
Irinotecan Sixth Affiliated Hospital, Sun Yat-sen University | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →